ETF Holdings Breakdown of MLTX

Stock NameMoonLake Immunotherapeutics
TickerMLTX(USD) NASDAQ
TYPECommon Stock
CountryUSA

News associated with MLTX

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.50 Consensus Price Target from Analysts
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) has been assigned a consensus rating of “Buy” from the eight brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. […] - 2025-04-25 05:52:47
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sets New 12-Month Low – What’s Next?
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) hit a new 52-week low during trading on Monday . The stock traded as low as $34.13 and last traded at $35.04, with a volume of 339603 shares. The stock had previously closed at $37.21. Analyst Ratings Changes MLTX has been the topic of a number of recent […] - 2025-04-08 07:50:55
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.50 Average PT from Analysts
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) has been assigned an average rating of “Buy” from the eight brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. […] - 2025-03-31 05:46:59
MoonLake Immunotherapeutics (NASDAQ:MLTX) Now Covered by Royal Bank of Canada
Royal Bank of Canada assumed coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a research report released on Tuesday, Marketbeat.com reports. The brokerage issued an outperform rating and a $67.00 price target on the stock. Several other analysts have also recently commented on the company. HC Wainwright reissued a “buy” rating and […] - 2025-03-19 07:12:49
Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $83.20
Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) have earned a consensus recommendation of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-03-06 06:45:40
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Holdings Cut by Handelsbanken Fonder AB
Handelsbanken Fonder AB reduced its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) by 14.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 11,100 shares of the company’s stock after selling 1,900 shares during the period. Handelsbanken Fonder AB’s holdings in MoonLake Immunotherapeutics were worth $601,000 at the end of the most […] - 2025-03-02 10:27:07

MLTX institutional holdings

The following institutional investment holdings of MLTX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 15,357USD 610,287
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 21,127USD 839,587 5.4%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 521USD 20,705
Total =37,005 USD 1,470,579
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.